– USA, MD – Clear Guide Medical, Inc., a commercial-stage image-fusion medical device company, today announced that it appointed Bob Cathcart to lead the Baltimore-based Company. Cathcart has worked in sales, marketing and international operations for medical device companies for 33 years, most recently as SVP of Global Sales at Hansen Medical, a Silicon Valley leader in Intra-Vascular Robotics.
During his career, Cathcart also served as Divisional President of Datascope Interventional Products, a company focused on vascular closure devices and devices for chronic dialysis, which was sold to Maquet in 2009. Cathcart was President and CEO of FlowCo Inc., a preclinical company focused in the Interventional Cardiology Space.
“Bob’s extensive professional experience in the medical industry and as an entrepreneur is the perfect fit for our expansion objectives,” said Jim Condon, a member of the board of directors. “He understands exactly the right approach in steering the company through its expanded launch in the marketplace and will guide us through this crucial growth phase.”
Cathcart succeeds Dorothee Heisenberg, who is a co-founder of the company and has led Clear Guide Medical since 2014. Dr. Heisenberg will remain with the company as Executive Vice President.
About Clear Guide Medical
Clear Guide Medical, Inc., a privately-held company headquartered in Baltimore, MD, develops innovative technologies to provide image fusion and Computer-Assisted Instrument Guidance for minimally invasive medical procedures. The Clear Guide Medical systems are an accessory to most commercial ultrasounds.
For more information : http://www.clearguidemedical.com
- Disclaimer - News, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.
Comments are closed.